1 / 75

OSTEOARTHRITIS

OSTEOARTHRITIS. Two Major Forms of Musculoskeletal Pain. Articular Degenerative: Osteoarthritis (OA) Inflammatory: Rheumatoid Arthritis (RA), etc., Crystal-induced: Gout, CPPD Other Nonarticular Fibromyalgia Soft tissue trauma Tendonitis, Bursitis, etc.

jelani-norman
Télécharger la présentation

OSTEOARTHRITIS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. OSTEOARTHRITIS

  2. Two Major Forms of Musculoskeletal Pain • Articular • Degenerative: Osteoarthritis (OA) • Inflammatory: Rheumatoid Arthritis (RA), etc., • Crystal-induced: Gout, CPPD • Other • Nonarticular • Fibromyalgia • Soft tissue trauma • Tendonitis, Bursitis, etc.

  3. Arthritis Care: An Increasing Burden on Healthcare Resources Prevalence 49.8 (19.2) 50 40 28 (10.2) 30 Millions of Cases in US (% Population)* 15.8 (6.1) 20 2.1 (0.8) 10 0.6 (0.23) 0.3 (0.12) 0 Ankylosing spondylitis Other systemic connective- tissue disease Osteoarthritis Rheum. arthritis Soft-tissuedisease Osteoporosis† *Data for 1993/94 †NationalOsteoporosis Foundation. www.nof.org. Dec 6, 2000. The Arthritis Foundation Fact Book for the Media. Atlanta, Georgia. Arthritis Foundation; 1994:1–4.

  4. Arthritis • 43 Million people in the US have some form of arthritis • 2020 it is expected that 103 million people will be effected • For approximately 3 million people in the US, the primary cause of limitation of movement is arthritis

  5. Extent of Musculoskeletal Diseases in United States • 37.9 million people affected by arthritis • – 21 million with clinical signs and symptoms • of OA • – 2.1 million with RA • Data from 1990 • Lawrence et al. Arthritis Rheum. 1998;41:778–799. • 315 million physician visits/yr • 8 million hospital admissions/yr • 17 million people with activity limitation • 1.5 billion days of restricted activity/yr • Data from 1990–1992 • Yelin, Callahan. Arthritis Rheum. 1995;38:1351–1362.

  6. Economic Impact of MusculoskeletalConditions in the United States Direct Costs 12% 12% Direct medical costs $ 72.3 billion* Indirect costs (lost wages) $ 77.1 billion Total costs $149.4 billion (2.5% of GNP) Physician 5% Hospital Other provider Drugs 20% Nursing home Administrative 46% Other 1% 4% *In 1992 dollars Data from Yelin, Callahan. Arthritis Rheum. 1995;38:1351–1362.

  7. Osteoarthritis: AKA Degenerative Arthritis Osteoarthrosis Old Age Arthritis Degenerative Joint Disease Wear and Tear Arthritis DJD

  8. Osteoarthritis • Definition Slowly progressive deterioration of a joint in which localized loss of cartilage occurs in association with subchondral sclerosis, osteophytosis, cyst formation, and synovial thickening

  9. SOCIOECONOMIC IMPACT OF OA • Most common reason for physician visits in people >55 years of age • Lost and limited work days • Impaired leisure activities • Co-morbidity: Heart disease, depression, etc. • Cost = Billions

  10. Normal vs OA Joint Normal knee Osteoarthritic knee Thickened capsule Capsule Cyst formation Sclerosis in subchondral bone Cartilage Fibrillated cartilage Synovium Synovial hypertrophy Osteophyte formation Bone

  11. Presentation • Symptoms • Pain: worse during the day—with activity or after activity • Stiffness: Minimal in the morning (<30 min); gelling after inactivity • Range of motion: decreased • Signs • Crepitus • Swelling—variable effusions • Restricted movement • Bony enlargement • Joint instability

  12. Location & Prevalence of OA 80 Men 60 DIP 40 Knee 20 Hip 0 Prevalence of OA (%) 20 40 60 80 80 Women DIP 60 Knee 40 Hip 20 0 20 40 80 60 Age (years)

  13. Articular Cartilage • Integrity depends on a balance between degradation and synthesis of extra-cellular matrix constituents Homeostasis Degradation Synthesis

  14. Pathogenesis of OA Biomechanical Chondrocytes • ­ Matrix degradation • Cytokines • Enzymes • N.oxide • ¯ Matrix synthesis • IGF-1 • TGF-b Genetic Loss of matrix integrity Metabolic OA IGF = insulin-like growth factor; TGF = transforming growth factor

  15. Articular Cartilage • A specialized connective tissue “organ” with a highly ordered anatomic structure that is avascular and aneural • A sparse chondrocyte population is embedded in extra-cellular matrix composed predominantly of water, proteoglycans, and type II collagen • The mechanical properties of articular cartilage are attributable to the extra-cellular matrix

  16. Normal Hyaline Cartilage

  17. Cartilage Ultra-structure • Collagen fiber alignment assists distribution of forces • Chondrocyte morphology varies within the tissue

  18. Cartilage Structure • Proteoglycans attach to hyaluronic acid via link protein to form an “aggregate” or aggrecan • Aggrecan interactions dampen compressive loads • Type II Collagen encapsulates aggrecan and distributes forces, providing tensile strength and resisting shear

  19. Cartilage Structure

  20. Osteoarthritis Biochemistry • Proteoglycan changes Decreased () total proteoglycan (PG) content  hyaluronic acid (HA) content  aggregate size and aggregation of proteoglycans • Collagen Changes Ultrastructural changes in collagen Increased water content • Chondrocyte response division to form “clusters” cellular hypertrophy

  21. Osteoarthritis • Cytokines can promote degradation and inhibit synthesis of extra-cellular matrix constituents OA Degradation Synthesis

  22. OA: Cartilage Changes

  23. Osteoarthritic Cartilage

  24. Radiographic Findings • Bony sclerosis • Joint space narrowing • Marginal osteophytes • Subchondral cysts • Malalignment

  25. Osteoarthritis of hands

  26. Osteoarthritis of Hands: X-rays

  27. Osteoarthritis: Synovial Cyst

  28. Osteoarthritis of the Knees

  29. Osteoarthritis of the Knee Subchondral bone Femoral condyle Patella

  30. OA of the Hip • Pain often is located deep in the groin and radiates to the thigh • Check ROM

  31. Osteoarthritis Cervical Spine Narrowed Neural Foramina

  32. Osteoarthritis Lumbar Spine

  33. Diffuse Idiopathic Skeletal Hyperostosis (DISH)

  34. EPIDEMIOLOGY OF OA • Most common form of chronic arthritis • 1:5 affected worldwide, increases with age • >50% require medical therapy for pain and disability

  35. Risk Factors • Age • Female sex • Trauma • Obesity (micro-trauma) • Genetic or hereditary links • Neuromuscular dysfunction • Metabolic disorders

  36. WEIGHT AND OA Degree of Obesity RR(95% CI) (Range of BMI) Males Females Normal (>20 to 25) 1.00 1.00 Overweight (>25 to 30) 1.69(1.03-2.80) 1.89(1.24-2.87) Obese (>30 to 35) 4.78(2.77-8.27) 3.87(2.63-5.68) Very Obese(>35) 4.45(1.77-11.18) 7.37(5.15-10.53) Am J Epidemiol 1988;128:179

  37. Goals of Arthritis Therapy • Relieve pain/inflammation • Minimize risks of therapy • Retard disease progression • Provide patient education • Prevent work disability • Enhance quality of life and functional independence

  38. Drug Therapy Options in Osteoarthritis • Analgesics • NSAIDs (Rx, OTC), COX-2 Inhibitors • Topical agents • Intra-articular glucocorticoids • Intra-articular hyaluronan • Investigational agents

  39. American Pain SocietyTreatment of Chronic Pain in OA • Plus, as needed: • Nonpharmacologic interventions • Glucosamine • Tramadol • Adjunctives • Intra-articular hyaluronic acid • Surgical intervention • Mild pain • Little or no inflammation • Acetaminophen • Moderate to severe pain/inflammation • COX-2–specific inhibitor Continued pain? Yes Continued pain? Conduct GI risk-factor analysis • High risk • Nonselective NSAID plus PPI or misoprostol • Not high risk • Nonselective NSAID • Hyaluronic acid injection for knee pain • Glucocorticoid intra-articular injection for other joint pain Yes Continued pain? American Pain Society, 2002.

  40. ACR Osteoarthritis Guidelines ACR Subcommittee on OA Guidelines. Arthritis Rheum 2000; 43: 1905-1915

  41. ACR Osteoarthritis Guidelines Nonpharmacologic MeasuresCornerstone of Therapy ACR Subcommittee on OA Guidelines. Arthritis Rheum 2000; 43: 1905-1915

  42. Patient education Personalized social support through telephone contact Aerobic exercise program Range-of-motion exercises Assistive devices for ambulation Appropriate footwear Bracing Joint protection and energy conservation Self-management programs Weight loss (if overweight) Physical therapy Muscle-strengthening exercises Patellar taping Lateral-wedge insoles Occupational therapy Assistive devices for activities of daily living Nonpharmacologic Modalities ACR Subcommittee on OA Guidelines. Arthritis Rheum 2000; 43: 1905-1915

  43. Physical Therapy 6 Minute Walk WOMAC Deyle, et al., Ann. Int. Med. 2000: 132; 173-81

  44. Acetaminophenfor the relief of mild-to-moderate joint pain ACR Osteoarthritis Guidelines Nonpharmacologic Measures ACR Subcommittee on OA Guidelines. Arthritis Rheum 2000; 43: 1905-1915

More Related